Please login to the form below

Not currently logged in
Email:
Password:

FDA looks to regulate digital tools

US regulator adds new components to digital health plan

FDA

As digital health makes greater inroads into the life sciences sector, the US Food and Drug Administration (FDA) is looking to streamline and accelerate its reviews of these products.

FDA Commissioner Scott Gottlieb launched the Digital Health Innovation Action Plan last year, and the agency will be investigating the option of regulating digital tools as part of the drug review process.

The FDA plans to develop a new regulatory framework for reviewing 'software as a medical device' and has also issued guidance regarding the FDA’s regulatory process for digital tools.

Scott Gottlieb said: “We know that consumers and healthcare providers are increasingly embracing digital health technologies to inform everyday decisions.

“Given the benefits from empowering consumers, we believe the FDA must encourage the development of tools that can help people be more informed about their health.”

Aiming for a more ‘streamlined’ review, the FDA has updated the software precertification pilot programme and a working model of this will soon be released.

This model will outline critical components of the pilot such as precertification of companies, the premarket review process and post-market surveillance, according to the FDA.

Additionally, the US agency has issued draft guidance concerning the FDA’s stance on reviewing devices with multiple functions, confirming that it will take a hands-off approach towards certain functions of digital devices.

Gottlieb concluded that an 'efficient' approach would allow the agency to focus on those functions that the FDA oversees, while allowing the industry to modernise digital tools to deliver additional benefits.

Article by
Gemma Jones

4th May 2018

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....